Pepgen reports second quarter 2023 financial results and recent corporate developments

– phase 2 open-label connect1-edo51 study open in canada – – potentially registrational, randomized, double-blind, placebo-controlled phase 2 connect2-edo51 multinational study expected to be initiated in the second half of 2023 – – continue to pursue global strategy of initiating freedom-edodm1 clinical study in geographies outside the u.s. – – continue to work closely with fda to lift the clinical hold and initiate the phase 1 freedom-edodm1 study in the u.s. as quickly as feasible – – ended second quarter 2023 with cash and cash equivalents of $147.0 million; cash runway expected into 2025 – boston, aug. 08, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended june 30, 2023 and highlighted recent corporate developments. “pepgen continues to make strong progress across our pipeline of clinical and pre-clinical stage conjugated oligonucleotide therapies for neuromuscular and neurological diseases," said james mcarthur, ph.d.
PEPG Ratings Summary
PEPG Quant Ranking